Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. [PDF]
Eyre TA +15 more
europepmc +1 more source
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia. [PDF]
Barber VS +7 more
europepmc +1 more source
Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study. [PDF]
Maruyama D +6 more
europepmc +1 more source
Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control. [PDF]
Lyu LW +8 more
europepmc +1 more source
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. [PDF]
Hess G +24 more
europepmc +1 more source
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. [PDF]
An G +15 more
europepmc +1 more source
Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies. [PDF]
Kumagai Y +4 more
europepmc +1 more source
Successful Treatment of Rituximab-Refractory Waldenstrom Macroglobulinemia-Related Kidney Damage With Bruton Tyrosine Kinase Inhibitor. [PDF]
Nie G +6 more
europepmc +1 more source
Bruton tyrosine kinase inhibitor in non-IgM lymphoplasmacytic lymphoma: a case report and literature review. [PDF]
Ito K, Hirano K, Sekiguchi N.
europepmc +1 more source
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. [PDF]
Weber MS, Nicholas JA, Yeaman MR.
europepmc +1 more source

